The Q1 results confirm accelerating COVID-19 revenue erosion and deepening operating losses as the company invests heavily in oncology pipeline. The $1.0B buyback provides a floor but does not offset fundamental deterioration. The manufacturing consolidation signals management's recognition of overcapacity but carries execution risk and upfront costs. Key catalysts to watch: Phase 2 pumitamig data at ASCO (May 29-June 2), trastuzumab pamirtecan BLA filing timeline, and interim data from multiple late-stage trials expected through 2026.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $95.50entry
- T+1 · 7mo ago −0.25%α −1.64% · $95.26
- T+5 · 6mo ago −1.93%α −3.91% · $93.66
- T+20 · 6mo ago −6.66%α −11.61% · $89.14
- T+60 · 4mo ago −2.77%α −5.51% · $92.85
Price Chart
How similar events traded
Executive Summary
BioNTech reported Q1 2026 results with total revenue of €118.1M, down 35% YoY from €182.8M, driven by a 50% decline in COVID-19 vaccine revenue to €66.9M. Net loss widened to €531.9M (€2.10 per share) from €415.8M (€1.73 per share) in Q1 2025, as R&D spending increased 6% to €557.0M and operating loss grew to €677.5M. Post-period, the company announced a $1.0B ADS repurchase program and a major manufacturing footprint consolidation affecting up to ~2,000 positions across multiple sites.
Key Facts
- Q1 2026 total revenue €118.1M, down 35% YoY from €182.8M
- COVID-19 vaccine revenue fell 50% YoY to €66.9M
- Net loss widened to €531.9M (€2.10/share) from €415.8M (€1.73/share)
- Operating loss increased to €677.5M from €534.1M
- R&D expenses rose 6% to €557.0M; sales & marketing up 104% to €27.9M
- Cash & investments totaled €16.76B as of March 31, 2026
- Post-period: $1.0B ADS repurchase program authorized
- Post-period: Manufacturing consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites affecting ~1,860 positions; JPT exit affecting ~140 positions
- Impairment of €29.9M on BNT331 program (paused)
- Pipeline prioritization costs of €18.7M in Q1
Financial Impact
Revenue decline of €64.7M (35% YoY); net loss increase of €116.1M (28% YoY); operating loss increase of €143.4M (27% YoY)
Risk Factors
- Continued COVID-19 revenue decline with no near-term replacement revenue stream
- Manufacturing consolidation execution risk and potential cash costs
- Multiple ongoing patent litigations (Moderna, GSK, Arbutus, Bayer) with uncertain outcomes
- Heavy R&D spend may not yield approved products for years
- Pipeline prioritization may lead to further program discontinuations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000031 |
| Document: form6-kq12026quarterlyrepo.htm | 0001776985-26-000031 |
| Document: 0001776985-26-000031-index-headers.html | 0001776985-26-000031 |
| Document: 0001776985-26-000031-index.html | 0001776985-26-000031 |
| Document: 0001776985-26-000031.txt | 0001776985-26-000031 |
Track record
38 reports on BNTX
4 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 10 of 15 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers